August 24, 2021 12:19:40
- Lexaria Bioscience is a drug delivery technology innovator whose flagship technology, DehydraTECH(TM), provides a means of enhancing substances’ delivery time to increase their effectiveness without adverse effects
- A new podcast by NetworkNewsAudio highlights DehydraTECH’s successes in trials that measure blood pressure reduction using DehydraTECH-enhanced CBD in comparison with generic controls
- The DehydraTECH technology is also being analyzed for effectiveness in combatting inflammatory conditions, viral illnesses and alternatives to the lung-harming effects of smoking
- The company’s most recent filing with the SEC notes that its revenues more than doubled between May 2020 and May 2021, driven largely by product sales and licensing agreements
A new podcast highlights the effectiveness enhancement efforts by technology innovator
Lexaria Bioscience (NASDAQ: LEXX) for treating high blood pressure (hypertension), a key risk factor for both heart disease and stroke that is common in the world’s adult populations, including in the United States.
The podcast (
https://cnw.fm/Zf5i6) reviews many important entrepreneurial tips to business owners from Lexaria CEO Chris Bunka. It also notes that nearly half of all Americans have high blood pressure but only about 24 percent of those afflicted with it — many of whom are younger than 40. One of the most insidious aspects of high blood pressure is…
Read More>>
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at
https://cnw.fm/LEXX
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing
CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit
https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:
https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW?
Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the
InvestorBrandNetwork.